Ivermectin dan Covid-19: Sebuah Tinjauan Literatur

Henry Wijaya; Niluh Ayu Sri Saraswati; Devinqa Adhimah Amanda

doi:10.47679/makein.202119

Published: 5 April 2021

Ivermectin dan Covid-19: Sebuah Tinjauan Literatur

Henry Wijaya
Niluh Ayu Sri Saraswati
Devinqa Adhimah Amanda

Vol. 2 No. 1: April 2021 | Pages: 9-15

DOI: 10.47679/makein.202119 Reader: 1991 times PDF Download: 3192 times

Abstract

Coronavirus disease (COVID-19) is an infectious disease that has been declared a pandemic by WHO and has become a case of a health emergency in the world. This disease is caused by the novel coronavirus (SARS-CoV-2) which was first identified in China. Until now, various studies have been conducted to find the most effective drug in eradicating this pandemic. Ivermectin, an anti-parasitic drug, is known to have antiviral properties by inhibiting the entry of viruses into the cells. On this basis, Ivermectin is believed to be capable of being one of the COVID-19 therapies. This literature review is a review of emerging cases, namely COVID-19 and its relation to Ivermectin, using the published data obtained through Google Scholar, PubMed, and WHO dataIvermectin, a parasitic agent that has been approved by the FDA, was able to prevent viral proteins from entering the host cell nucleus. Ivermectin was also shown to be able to accelerate viral clearance in the body compared to the placebo group and show a significant reduction in CRP and LDH levels. Patients receiving ivermectin also showed a lower incidence of respiratory distress and a shorter duration of hospitalization. The administration of ivermectin as a COVID-19 drug can have a positive impact on patients both clinically and in the laboratory.

ABSTRAK: Penyakit coronavirus (COVID-19) adalah suatu penyakit infeksi yang telah diumumkan sebagai suatu pandemi oleh WHO dan menjadi kasus gawat darurat kesehatan di dunia. Penyakit ini disebabkan oleh novel coronavirus (SARS-CoV-2) yang pertama kali di China. Hingga saat ini berbagai penelitian telah dijalankan untuk menemukan obat yang paling efektif dalam membasmi pandemi ini. Ivermectin, obat anti parasit, diketahui memiliki sifat anti virus dengan cara menghambat proses masuknya virus ke dalam sel tubuh. Dengan dasar ini, Ivermectin dipercayai mampu menjadi salah satu terapi COVID-19. Tinjauan literatur ini merupakan sebuah tinjauan kasus emerging yakni COVID-19 dan kaitannya dengan Ivermectin, dimana sumber tulisan didapatkan melalui data google cendekia, PubMed, dan WHO. Ivermectin, suatu agen parasit yang telah disetujui oleh FDA, mampu mencegah protein virus masuk ke dalam nukleus sel host. Ivermectin juga dibuktikan mampu mempercepat klirens virus di dalam tubuh dibandingkan dengan kelompok placebo dan menunjukkan penurunan yang signifikan pada kadar CRP dan LDH. Pasien-pasien yang mendapatkan ivermectin juga menunjukkan angka kejadian distres nafas yang lebih rendah dan durasi rawat inap yang lebih singkat. Pemberian ivermectin sebagai obat COVID-19 mampu memberikan dampak yang positif kepada pasien baik secara klinis maupun laboratorium.

References

Ahidjo, B. A., Loe, M. W., Ng, Y. L., Mok, C. K., & Chu, J. J. (2020). Current Perspective of Antiviral Strategies against COVID-19. ACS Infect Dis, acsinfecdis.0c00236. doi: 10.1021/acsinfecdis.0c00236
Ali, M. J., Hanif, M., Haider, M. A., Ahmed, M. U., Sundas, F., Hirani, A.,Karim, A. H. (2020). Treatment Options for COVID-19: A Review. Front Med (Lausanne), 7: 480. doi: 10.3389/fmed.2020.00480
Alam, M. T., Murshed, R., Bhiuyan, E., Saber, S., Alam, R. F., & Robin, R. C. (2020). A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons, 38(July), 10–15. doi: 10.3329/jbcps.v38i0.47512
Ahmed, S., Mahbubul, M., Ross, A. G., Sharif, M., Clemens, J. D., Kibtiya, M., Swe, C., Zaman, K., Somani, J., & Yasmin, R. (2020). A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Disease, 103(January), 214–216. doi: 10.1016/j.ijid.2020.11.191
Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R. (2016). A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host and Microbe, 20(2), 259–270. doi: 10.1016/ j.chom.2016.07.004
Bleyzac, N., Goutelle, S., Bourguignon, L., & Tod, M. (2020). Azithromycin for COVID-19: More Than Just an Antimicrobial? Clinical Drug Investigation, 40(8), 683–686. doi: 10.1007/s40261-020-00933-3
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagsta, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178(January), 104787. doi: 10.1016/j.antiviral.2020.104787
Canga, A. G., Prieto, A. M. S., Diez Liébana, M. J., Martínez, N. F., Sierra Vega, M., & García Vieitez, J. J. (2008). The pharmacokinetics and interactions of ivermectin in humans - A mini-review. AAPS Journal, 10(1), 42–46. doi: 10.1208/s12248-007-9000-9
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Napoli, R. D. (2020). Features, Evaluation, and Treatment of Coronavirus. StatPearls [Internet]. Retrieve from : https://www.ncbi.nlm.nih.gov/books/NBK554776/
Chowdhury, A. T. M. M., Shahbaz, M., Karim, M. R., Islam, J., Guo, D., & He, S. (2020). A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients. Research Square, 1–19. doi: 10.21203/rs.3.rs-38896/v1
Chu, D. K., Kim, L. H.-Y., Young, P. J., Zamiri, N., Almenawer, S. A., Roman, J., Alhazzani, W. ( 2018). Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet, 391(10131):1693-1705. doi: 10.1016/S0140-6736(18)30479-3
Crump, A., & Omura, S. (2011). Ivermectin, “Wonder drug” from Japan: The human use perspective. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 87(2), 13–28. doi: 10.2183/pjab.87.13
Delvecchio, R., Higa, L. M., Pezzuto, P., Valadão, A. L., Garcez, P. P., Monteiro, F. L., et al. (2016). Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. Viruses, 8(12): 322. doi: 10.3390/v8120322
Donde, O. O., Atoni, E., Muia, A. W., & Yilla, P. T. (2021). COVID-19 pandemic: Water, sanitation and hygiene (WASH) as a critical control measure remains a major challenge in low-income countries. Water Res, 191: 116793. doi: 10.1016/j.watres.2020.11679 3.
Elkholy, K. O., Hegazy, O., Erdinc, B., & Abowali, H. (2020). Ivermectin: A Closer Look at a Potential Remedy. Cureus, 12(9). doi:10.7759/cureus.10378
Farias, K. J., Machado, P. R., de Almeida Junior, R. F., de Aquino, A. A., & da Fonseca, A. B. (2014). Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol. Immunol, 318-326. doi: 10.1111/1348-0421.12154
Gorial, F. I., Mashhadani, S., Sayaly, H. M., Dakhil, B. D., AlMashhadani, M. M., Aljabory, A. M., Abbas, H. M., Ghanim, M., & Rasheed, J. I. (2020). Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial). MedRxiv, 2(December 2019), 2–13. doi: 10.1101/2020.07.07.20145979
Gupta, D., Sahoo, A. K., & Singh, A. (2020). Ivermectin: potential candidate for the treatment of Covid 19. Brazilian Journal of Infectious Diseases, 24(4), 369–371. doi: 10.1016/j.bjid.2020.06.002
Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K., & Abdulamir, A. S. (2020). Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. MedRxiv, 48, 2020.10.26.20219345.
Heidary, F., & Gharebaghi, R. (2020). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. Journal of Antibiotics, 73(9), 593–602.
Ibáñez, S., Martínez, O., Valenzuela, F., Silva, F., & Valenzuela, O. (2020). Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Clinical Rheumatology, 39(8), 2461–2465. doi: 10.1007/s10067-020-05202-4
Jans, D. A., & Wagstaff, K. M. (2020). The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ? Biochemical and Biophysical Research Communications, January. doi: 10.1016/j.bbrc.2020.10.042
Kahn, M., Santhosh, S., Tiwari, M., Rao, L., & Parida, M. (2010). Assessment of In Vitro Prophylactic and Therapeutic Efficacy of Chloroquine Against Chikungunya Virus in Vero Cells. Journal of Medical Virology, 82, 817–824. doi: 10.1128/microbiolspec. EI10-0017-2016
Khan, S. I., Khan, S. I., Debnathc, C. R., Nath, P. N., Mahtab, M. Al, Nabeka, H., Matsuda, S., & Akbar, S. M. F. (2020). Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Arch Bronconeumol, 56(12), 828–830. doi : 10.1016/j.arbres.2020.08.007
Khuroo, M. S. (2020). Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. Int J Antimicrob Agents, 56(3): 106101. doi: 10.1016/j.ijantimicag.2020.106101
Li, H., Liu, S.-M., Yu, X.-H., & Tang, C.-K. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents, 55(5): 105951. doi: 10.1016/j.ijantimicag. 2020.105951
Matthay, M. A., & Thompson, T. B. (2020). Dexamethasone in hospitalized patients with COVID-19: addressing uncertainties. The Lancet, 1170 - 1172. doi: 10.1016/S2213-2600(20)30503-8
Miranda, C., Silva, V., Capita, R., Alonso-Calleja, C., Igrejas, G., & Poeta, P. (2020). Implications of antibiotics use during the COVID-19 pandemic: Present and future. Journal of Antimicrobial Chemotherapy, 75(12), 3413–3416. doi: 10.1093/ jac/dkaa350
Rajter, J. C., Sherman, M. S., Fatteh, N., Vogel, F., Sacks, J., & Rajter, J. J. (2021). Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest, 159(1), 85–92. doi: 10.1016/j.chest.2020.10.009
Shenoy, N., Luchtel, R., & Gulani, P. (2020). Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting? BMC Med, 18: 260. doi: 10.1186/s12916-020-01735-2
Sieswerda, E., Boer, M. G. J. De, Bonten, M. M. J., Boersma, W. G., Jonkers, E., Aleva, R. et al. (2020). Recommendations for antibacterial therapy in adults with COVID-19 e an evidence based guideline. Clin Microbiol Infect, 27(January), 61–66. doi: 10.1016/j.cmi.2020.09.041
Singh, A. K., Majumday, S., Singh, R., & Anoop, M. (2020). Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab Syndr, 14(5): 971–978. doi: 10.1016/j.dsx.2020.06.054
Singhai, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr, 281-286. doi: 10.1007/s12098-020-03263-6
Wang, J.-W., Yang, L., Luo, R.-G., & Xu, J.-F. (2020). Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin Microbiol Infect, 26(9): 1171–1177. doi: 10.1016/j.cmi.2020.06.020
Weiss, S. R., & Martin, S. N. (2005). Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiol Mol Biol Rev, 635-664. doi: 10.1128/MMBR.69.4.635-664.2005
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., et al. (2020). Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 180(7), 1–11. doi: 10.1001/jamainternmed.2020.0994
Yavuz, S. Ş., & Ünal, S. (2020). Antiviral treatment of COVID-19. Turk J Med Sci, 50(3): 611–619. doi: 10.3906/sag-2004-145.

Rights and permissions

© The Author(s) 2021
Open Access This article is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), which permits others to share, adapt, and redistribute the material in any medium or format, even for commercial purposes, provided appropriate credit is given to the original author(s) and the source, a link to the license is provided, and any changes made are indicated. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/4.0/.

Fulltext

Keywords

ivermectin
covid-19
anti parasit

Author Information

Henry Wijaya

University of Brawijaya, Faculty of Medicine, Indonesia.

ORCID : https://orcid.org/0000-0003-1566-2392

Niluh Ayu Sri Saraswati

Fakultas Kedokteran Universitas Udayana, Indonesia.

ORCID : https://orcid.org/0000-0001-8084-4788

Devinqa Adhimah Amanda

Fakultas Kedokteran Universitas Sumatera Utara, Indonesia.

ORCID : https://orcid.org/0000-0002-9260-093X

Article History

Submitted: 29 January 2021
Accepted: 13 March 2021
Published: 5 April 2021

How to Cite This

Wijaya, H., Saraswati, N. A. S., & Amanda, D. A. (2021). Ivermectin dan Covid-19: Sebuah Tinjauan Literatur. Majalah Kesehatan Indonesia, 2(1), 9–15. https://doi.org/10.47679/makein.202119